Listen and follow our podcasts on:

This educational programme is supported by an Independent Educational Grant from Bayer

In this podcast, Prof. Jonathan Trent and Prof. Robin Jones discuss what's new in sarcoma management from CTOS 2022, including insights from the DeFi, rEECur and ENLIVEN studies.

 

Clinical Takeaways

  • New agents for patients with advanced undifferentiated liposarcoma are in development
  • Active salvage therapy is an option in Ewing sarcoma 
  • Oral TKIs can provide relief for patients with Tenosynovial Giant Cell Tumour

 

In this podcast, Prof. Jonathan Trent and Prof. Robin Jones discuss what’s new in patient management in sarcoma from CTOS 2022.

The Connective Tissue Oncology Society is an international group of physicians and scientists with a primary interest in the tumours of connective tissues. With nearly 600 attendees, 10 sessions specific for sarcoma, and over 300 posters, CTOS 2022 took place between November 16 and 19 in Vancouver, BC, Canada.

Clinical practice and patient management highlights covered in the podcast include insights from the DEFI study on desmoid tumour, the REECUR study for Ewing sarcoma, and the ENLIVEN study for gastrointestinal stromal tumour (GIST). In addition, early studies with potential clinical impact are discussed.

Dr Jonathan C. Trent earned his MD and PhD in cancer biology from The University of Texas Health Science Center where he also completed a residency in internal medicine. He then completed a fellowship in medical oncology at The University of Texas M. D. Anderson Cancer Center while serving as chief fellow. Prior to joining the University of Miami, Sylvester Comprehensive Cancer Center, he held an appointment as associate professor of medicine in the Department of Sarcoma Medical Oncology, Division of Cancer Medicine at the University of Texas M. D. Anderson Cancer Center in Houston. Dr Trent is currently the Associate Director for Clinical Research, the Director of the Bone and Soft-tissue Sarcoma Group and Medical Director of the Precision Medicine Initiative at the Sylvester Comprehensive Cancer Center. Dr Trent’s interests are in the clinical and translational research of sarcomas, direct care of sarcoma patients, and education about sarcoma. As Associate Director for Clinical Research, his goal is to help Sylvester Faculty develop clinical trials that provide clinically effective and scientifically exciting therapy to cancer patients of South Florida and beyond. The major focus of his clinical, educational and research efforts are with gastrointestinal stromal tumor (GIST), chondrosarcoma, and other sarcomas. The major efforts of Dr Trent’s research focus on understanding the mechanisms of action and resistance of imatinib in GIST and other sarcomas while striving toward improved therapeutic options. His work involves the use of novel preoperative/postoperative clinical trials, prospectively acquired tumor tissue, cell lines, archival tissue, as well as collaborations with disciplines such as the genomics facility, surgical oncology, pathology, radiology and interventional radiology.

Robin Jones is a medical oncologist specialising in the treatment of bone and soft tissue sarcomas and Head of the Sarcoma Unit at The Royal Marsden. He has experience in conducting Phase I, II and III trials, as well translational studies in sarcomas. Professor Jones trained in medical oncology at The Royal Marsden and between 2010 and 2014 he was Head of the Sarcoma Program at the University of Washington/Fred Hutchinson Cancer Research Center in Seattle. His main research interest focuses on clinical trials and translational research in sarcomas

Listen and follow our podcasts on:

This educational programme is supported by an Independent Educational Grant from Bayer

In this podcast, Prof. Jonathan Trent and Prof. Robin Jones discuss what's new in sarcoma management from CTOS 2022, including insights from the DeFi, rEECur and ENLIVEN studies.

 

Clinical Takeaways

  • New agents for patients with advanced undifferentiated liposarcoma are in development
  • Active salvage therapy is an option in Ewing sarcoma 
  • Oral TKIs can provide relief for patients with Tenosynovial Giant Cell Tumour

 

In this podcast, Prof. Jonathan Trent and Prof. Robin Jones discuss what’s new in patient management in sarcoma from CTOS 2022.

The Connective Tissue Oncology Society is an international group of physicians and scientists with a primary interest in the tumours of connective tissues. With nearly 600 attendees, 10 sessions specific for sarcoma, and over 300 posters, CTOS 2022 took place between November 16 and 19 in Vancouver, BC, Canada.

Clinical practice and patient management highlights covered in the podcast include insights from the DEFI study on desmoid tumour, the REECUR study for Ewing sarcoma, and the ENLIVEN study for gastrointestinal stromal tumour (GIST). In addition, early studies with potential clinical impact are discussed.

Dr Jonathan C. Trent earned his MD and PhD in cancer biology from The University of Texas Health Science Center where he also completed a residency in internal medicine. He then completed a fellowship in medical oncology at The University of Texas M. D. Anderson Cancer Center while serving as chief fellow. Prior to joining the University of Miami, Sylvester Comprehensive Cancer Center, he held an appointment as associate professor of medicine in the Department of Sarcoma Medical Oncology, Division of Cancer Medicine at the University of Texas M. D. Anderson Cancer Center in Houston. Dr Trent is currently the Associate Director for Clinical Research, the Director of the Bone and Soft-tissue Sarcoma Group and Medical Director of the Precision Medicine Initiative at the Sylvester Comprehensive Cancer Center. Dr Trent’s interests are in the clinical and translational research of sarcomas, direct care of sarcoma patients, and education about sarcoma. As Associate Director for Clinical Research, his goal is to help Sylvester Faculty develop clinical trials that provide clinically effective and scientifically exciting therapy to cancer patients of South Florida and beyond. The major focus of his clinical, educational and research efforts are with gastrointestinal stromal tumor (GIST), chondrosarcoma, and other sarcomas. The major efforts of Dr Trent’s research focus on understanding the mechanisms of action and resistance of imatinib in GIST and other sarcomas while striving toward improved therapeutic options. His work involves the use of novel preoperative/postoperative clinical trials, prospectively acquired tumor tissue, cell lines, archival tissue, as well as collaborations with disciplines such as the genomics facility, surgical oncology, pathology, radiology and interventional radiology.

Robin Jones is a medical oncologist specialising in the treatment of bone and soft tissue sarcomas and Head of the Sarcoma Unit at The Royal Marsden. He has experience in conducting Phase I, II and III trials, as well translational studies in sarcomas. Professor Jones trained in medical oncology at The Royal Marsden and between 2010 and 2014 he was Head of the Sarcoma Program at the University of Washington/Fred Hutchinson Cancer Research Center in Seattle. His main research interest focuses on clinical trials and translational research in sarcomas
Programme summary
  • clock Duration 22 MIN
  • clock Downloadable resources Yes
  • pdf Transcript
  • clock Language(s) flag
Listen to the podcast now
Share this programme
This educational programme is supported by an Independent Educational Grant from Bayer
Supporter Acknowledgement
This educational programme is supported by an Independent Educational Grant from Bayer
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
SARCOMA CONNECT

SARCOMA CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from Bayer and Karyopharm Therapeutics.

Meet the experts Independent IME approved
Programme summary
  • clock Duration MIN
  • clock Language(s) flag
Listen to the podcast now
Share this programme
This educational programme is supported by an Independent Educational Grant from Bayer
Supporter Acknowledgement
This educational programme is supported by an Independent Educational Grant from Bayer
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
SARCOMA CONNECT

SARCOMA CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from Bayer and Karyopharm Therapeutics.

Meet the experts Independent IME approved

Other programmes of interest

podcast Video podcast
Oncology 
Metastatic breast cancer: Understanding HER2-low and HER2-ultralow classification

A novel therapeutic framework 

Experts
Dr Komal Jhaveri, Oncology Brothers (Moderators)
  • download Downloadable
    Resources
  • clock 25 MIN
  • calendar Dec 2025
  • Non-accredited Independent Medical Education

Educational programme supported by an Independent Educational Grant from AstraZeneca 
patient-support Patient Support

Episode

2

of 2

episode
Oncology Endocrinology Rare diseases 
Thriving beyond an EP-NEC diagnosis

Perspectives on treatment and care 

Experts
Jessica Thomas
Endorsed by
NET-Research-Foundation Minkhas mission
  • clock 4 MIN
  • calendar Dec 2025
  • Non-accredited Independent Medical Education

Educational programme supported by an Independent Educational Grant from Boehringer Ingelheim 
patient-support Patient Support

Episode

1

of 2

episode
Oncology Endocrinology Rare diseases 
Navigating extrapulmonary neuroendocrine carcinoma (EP-NEC)

Insights for patients and care partners 

Experts
Meredith Cummins
Endorsed by
INCA
NeuroEndocrine Cancer Australia Neuroendocrine Cancer Foundation NET-Research-Foundation
Neuroendocrine Cancer UK Minkhas mission
  • clock 5 MIN
  • calendar Dec 2025
  • Non-accredited Independent Medical Education

Educational programme supported by an Independent Educational Grant from Boehringer Ingelheim 
eks
EKS / On-demand webinar
Oncology 
ESMO 2025: Gastric and gastroesophageal cancer insights for clinical practice

On-demand materials from an Experts Knowledge Share event

Experts
Dr Elizabeth Smyth, Prof. Aziz Zaanan, Prof. Markus Moehler
Endorsed by
ESDO
Digestive Cancers Europe
ICAN international cancer advocacy network
  • download Downloadable
    Resources
  • clock 67 MIN
  • calendar Dec 2025
  • Non-accredited Independent Medical Education

Educational programme supported by an Independent Educational Grant from Amgen.